| Objective: To investigate the changes and clinical significance of dendritic cell subsetmDC and pDC expression in hepatocellular carcinoma (HCC) patients after transcatheterarterial chemoembolization (TACE) with microparticle embolic agent.Methods: The experiment was divided into3groups, the treatment group: GSMs-conventional TACE group; control group1: liver cirrhosis patients; control group2: normalcontrol group. AFP and other biochemical tests were performed one day before treatment and4,7,15and30days after TACE in treatment group.10ml venous blood was collected fromthe patients in treatment group one day before surgery and4,7,15and30days after TACE.10ml venous blood from other two groups was also collected once. Peripheral bloodmononuclear cells (PBMC) were separated by using Ficoll-Hypaque density gradientcentrifugation. Marked FITC (CD3, CD14, CD16, CD19, CD20, CD56), APC-CD11c+,Pecy-5-CD123and PE-HLA DR monoclonal antibodies, flow cytometry was used to countthe frequencies of mDC (HLA-DR and CD11c+double positive cells), pDC (HLA-DR andCD123+double positive cells) in PBMC. Written informed consent was obtained from allvolunteers and patients.Results:1. The treatment group: this group consisted of a total of20cases of HCC patients,TACE was performed using gelatin sponge microparticles (GSMs，150-350μm or350-350μm); Liver cirrhosis group:10cases of posthepatitic cirrhosis; Normal control group;10healthy volunteers.2. Compared with normal control group, mDC, pDC in peripheral blood mononuclearcells (PBMC) of treatment group was significantly lower, the difference was statisticallysignificant （0.16±0.07VS0.44±0.18，t=6.1678,P=0.000；0.12±0.10VS0.28±0.12，t=3.8668,P=0.0005）; Similarly compared with cirrhosis group, the number of mDC, pDC inPBMC in treatment group was significantly lower, the difference was statistically significant（0.16±0.07VS0.31±0.16，t=3.6032,P=0.000；0.12±0.10VS0.20±0.08，t=2.1966,P=0.037）.3. In the treatment group after7days, the mDC difference was significant comparedwith preoperative （0.29±0.15VS0.16±0.07，t=2.4835,P=0.023）, however there was nosignificant difference after4,15,30days of TACE compared with the preoperative,（0.12±0.11VS0.16±0.07,t=0.9701,P=0.345；0.19±0.10VS0.16±0.07,t=0.7771,P=0.447； 0.17±0.09VS0.16±0.07,t=0.2773,P=0.785）; there was no statistical difference in pDC beforeand after treatment （0.10±0.07VS0.12±0.10,t=0.5818,P=0.601；0.13±0.09VS0.12±0.10,t=0.2351,P=0.0.817；0.11±0.06VS0.12±0.10,t=0.2711,P=0.789；0.11±0.07VS0.12±0.10,t=0.2591,P=0.799）.4. There was no correlation between peripheral blood mDC (7days after GSMs-TACE)and serum ALT, AST （r=0.007,P=0.978,r=0.053,P=0.824）.Conclusion:1. GSMs-TACE can promote the expression of mDC, thereby help to boost the DCantigen presenting in hepatocellular carcinoma.2. GSMs-TACE had no significant effect on pDC changes in peripheral blood, andtherefore may not be able to improve its mediated immune tolerance.3. The significant necrosis of liver tumors after GSMs-TACE could be a major incentiveto promote the expression of mDC. |
PDF Full Text Request